• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    DENTSPLY SIRONA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    6/12/25 5:20:23 PM ET
    $XRAY
    Medical/Dental Instruments
    Health Care
    Get the next $XRAY alert in real time by email
    8-K
    false 0000818479 0000818479 2025-06-12 2025-06-12
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of The Securities Exchange Act of 1934

    June 12, 2025

    Date of Report (Date of earliest event reported)

     

     

    DENTSPLY SIRONA Inc.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   0-16211   39-1434669

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    file number)

     

    (IRS Employer

    Identification No.)

     

    13320 Ballantyne Corporate Place, Charlotte, North Carolina   28277-3607
    (Address of Principal Executive Offices)   (Zip Code)

    (844) 848-0137

    (Registrant’s Telephone Number, Including Area Code)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Title of each class

     

    Trading
    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   XRAY   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01

    Entry into a Material Definitive Agreement

    On June 12, 2025, DENTSPLY SIRONA Inc. (the “Company”) issued $550,000,000 aggregate principal amount of the Company’s 8.375% Fixed-to-Fixed Reset Rate Junior Subordinated Notes due 2055 (the “Notes). The Notes were issued pursuant to the Company’s Registration Statement on Form S-3ASR, File No. 333-286281, dated March 31, 2025 (the “Notes Offering”).

    The Notes were issued under an Indenture, dated May 26, 2020 (the “Base Indenture”), between the Company and Computershare Trust Company, National Association (as successor to Wells Fargo Bank, National Association), as trustee (the “Trustee”), as supplemented by the Second Supplemental Indenture, dated June 12, 2025, between the Company and the Trustee (the “Second Supplemental Indenture” and, together with the Base Indenture, the “Indenture”).

    The Notes mature on September 12, 2055 and bear interest (i) from, and including, the original issuance date to, but excluding, September 12, 2030 (“First Reset Date”) at a rate of 8.375% per year and (ii) from, and including, the First Reset Date, during each Reset Period (as defined in the Second Supplemental Indenture), at a rate per year equal to the Five-year U.S. Treasury Rate (as defined in the Second Supplemental Indenture) as of the most recent Reset Interest Determination Date (as defined in the Second Supplemental Indenture) for such Reset Period plus a spread of 4.379%, to be reset on each Reset Date (as defined in the Second Supplemental Indenture); provided, that the interest rate during any Reset Period will not reset below 8.375% (which equals the initial interest rate on the Notes). Interest is payable on the Notes semi-annually in arrears on March 12 and September 12 of each year, beginning on September 12, 2025.

    The Company may redeem the Notes in whole or in part on one or more occasions at a price equal to 100% of the principal amount being redeemed, plus accrued and unpaid interest to, but excluding, the redemption date (i) on any day during the period commencing on the date that is 90 days prior to the First Reset Date and ending on and including the First Reset Date and (ii) after the First Reset Date, on any interest payment date for the Notes.

    Copies of the Base Indenture, the Second Supplemental Indenture and the form of the Notes are attached hereto as Exhibits 4.1, 4.2 and 4.3, respectively, to this Current Report on Form 8-K and are incorporated herein by reference. The above descriptions of the material terms of the Base Indenture, the Second Supplemental Indenture and the Notes do not purport to be complete and are qualified in their entirety by reference to such Exhibits.

    A copy of the opinion of DLA Piper LLP (US) relating to the legality of the issuance and sale of the Notes is attached as Exhibit 5.1 to this Current Report on Form 8-K.

     

    Item 1.02

    Termination of a Material Definitive Agreement

    On June 12, 2025, the Company used a portion of the proceeds from the Notes Offering to repay in full the outstanding principal and accrued interest due under the Company’s existing 364-day $435 million term loan (the “Bridge Loan Facility”). As a result of this repayment, the Bridge Loan Facility has been terminated (together with the agreements and instruments related thereto), and no additional interest or fees will accrue in respect of the Bridge Loan Facility. No early termination penalties or prepayment premiums were incurred by the Company in connection with the termination of the Bridge Loan Facility.

     

    Item 2.03

    Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

    The disclosure provided in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.

     

    Item 9.01

    Financial Statements and Exhibits

    (d) Exhibits

     

    Exhibit
    No.
       Description
    4.1    Indenture, dated as of May 26, 2020, between DENTSPLY SIRONA Inc. and Wells Fargo Bank, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on May 26, 2020)


    4.2    Second Supplemental Indenture, dated as of June 12, 2025, between DENTSPLY SIRONA Inc. and Computershare Trust Company, N.A.
    4.3    Form of 8.375% Junior Subordinated Notes due 2055 (included in Exhibit 4.1)
    5.1    Opinion of DLA Piper LLP (US)
    23.1    Consent of DLA Piper LLP (US) (included in Exhibit 5.1)
    104    Cover Page Interactive Data File (embedded within the Inline XBRL Document)


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        DENTSPLY SIRONA Inc.
    Date: June 12, 2025     By:  

    /s/ Richard C. Rosenzweig

          Richard C. Rosenzweig
         

    Executive Vice President, Corporate Development,

    General Counsel and Secretary

    Get the next $XRAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XRAY

    DatePrice TargetRatingAnalyst
    4/15/2025$14.00Overweight → Equal-Weight
    Morgan Stanley
    3/13/2025Buy → Hold
    Needham
    2/14/2025$20.00Equal Weight
    Wells Fargo
    1/23/2025$30.00 → $20.00Buy → Hold
    Jefferies
    1/7/2025$20.00Outperform → In-line
    Evercore ISI
    12/4/2024$21.00Neutral
    Mizuho
    11/7/2024Outperform → Market Perform
    Leerink Partners
    10/25/2024$34.00 → $29.00Buy
    Needham
    More analyst ratings

    $XRAY
    SEC Filings

    See more
    • DENTSPLY SIRONA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/12/25 5:20:23 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by DENTSPLY SIRONA Inc.

      8-K - DENTSPLY SIRONA Inc. (0000818479) (Filer)

      6/6/25 8:21:14 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form FWP filed by DENTSPLY SIRONA Inc.

      FWP - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      6/5/25 5:25:28 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP & CFO Garth Matthew E was granted 43,023 shares (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      6/3/25 4:48:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Garth Matthew E

      3 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      5/30/25 4:27:32 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Vergis Janet S. was granted 13,880 shares, increasing direct ownership by 46% to 43,981 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      5/27/25 5:26:57 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dentsply Sirona Prices Offering of $550 million of Junior Subordinated Notes

      CHARLOTTE, N.C., June 05, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced it has priced an offering (the "Offering") of $550 million aggregate principal amount of its 8.375% Junior Subordinated Notes due 2055 (the "notes"). The Offering is expected to close on June 12, 2025, subject to customary closing conditions. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030 (the "First Reset Date"). On and after the First Reset Date, the interest rate per year on the notes for each reset period will be equal to the five-year U.S. Treasury rate as of the most recent reset interest rate determinati

      6/5/25 5:35:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DENTSPLY SIRONA Inc.

      SC 13G/A - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      12/6/24 10:11:29 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/14/24 1:22:35 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by DENTSPLY SIRONA Inc.

      SC 13G - DENTSPLY SIRONA Inc. (0000818479) (Subject)

      11/12/24 4:23:31 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dentsply Sirona downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Dentsply Sirona from Overweight to Equal-Weight and set a new price target of $14.00

      4/15/25 9:24:19 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona downgraded by Needham

      Needham downgraded Dentsply Sirona from Buy to Hold

      3/13/25 7:58:34 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Wells Fargo initiated coverage on Dentsply Sirona with a new price target

      Wells Fargo initiated coverage of Dentsply Sirona with a rating of Equal Weight and set a new price target of $20.00

      2/14/25 7:09:40 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Lucier Gregory T bought $249,994 worth of shares (15,142 units at $16.51), increasing direct ownership by 23% to 81,971 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      3/3/25 6:33:03 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 8% to 66,730 units (SEC Form 4)

      4/A - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      1/29/25 6:14:01 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Director Lucier Gregory T bought $110,129 worth of shares (6,000 units at $18.35), increasing direct ownership by 7% to 71,730 units (SEC Form 4)

      4 - DENTSPLY SIRONA Inc. (0000818479) (Issuer)

      11/18/24 4:16:34 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Financials

    Live finance-specific insights

    See more
    • Dentsply Sirona Declares Quarterly Cash Dividend

      CHARLOTTE, N.C., May 27, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) announced that its Board of Directors declared a quarterly cash dividend of $0.16 per share of common stock, an indicated annual rate of $0.64 per share. The dividend is payable on July 11, 2025, to holders of record as of June 27, 2025. About Dentsply Sirona Dentsply Sirona is the world's largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and

      5/27/25 4:15:00 PM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Reports First Quarter 2025 Results

      Net sales of $879 million decreased (7.7%), organic sales decreased (4.4%) including a (4.0%) Byte sales impactGAAP gross margin of 53.0%, GAAP net income of $20 million or $0.10 per shareAdjusted gross margin of 56.3%, adjusted EBITDA margin of 19.0%, adjusted EPS of $0.43Maintaining FY25 outlook for organic sales and adjusted EPS; increasing reported sales due to F/X changes CHARLOTTE, N.C., May 08, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced its financial results for the first quarter of 2025. First quarter net sales of $879 million decreased (7.7%) (organic sales decreased (4.4%)) compared to the first quarter of 2

      5/8/25 6:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona to Host First Quarter Conference Call on May 8th

      CHARLOTTE, N.C., April 09, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that the Company will be hosting an investor conference call and live webcast on Thursday, May 8, 2025, at 8:30 am ET to review its first quarter financial results. A presentation related to the call will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. Conference Call / Webcast Information A live webcast will be available on the Investors section of the Company's website at https://investor.dentsplysirona.com. For those planning to participate on the call, please register at https://register-conf

      4/9/25 7:00:00 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care

    $XRAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Dentsply Sirona Appoints Matthew E. Garth as Chief Financial Officer

      CHARLOTTE, N.C., May 29, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Matthew E. Garth has been appointed Executive Vice President and Chief Financial Officer, effective May 30, 2025. Mr. Garth brings nearly 30 years of proven financial management expertise to Dentsply Sirona, with a focus on driving value creation. He most recently served as Chief Financial Officer & Chief Administrative Officer of The Scotts Miracle-Gro Company, a global leader of branded consumer lawn and garden products. Prior to ScottsMiracle-Gro, Mr. Garth held numerous financial leadership roles at large, multinational companies, including Min

      5/29/25 4:30:00 PM ET
      $MTX
      $SMG
      $XRAY
      Major Chemicals
      Industrials
      Agricultural Chemicals
      Medical/Dental Instruments
    • Dentsply Sirona Appoints David Ferguson as Global Business Unit Leader

      CHARLOTTE, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (XRAY) today announced that David Ferguson has been appointed Senior Vice President, Global Business Unit Leader, effective March 14, 2025. In this role he will lead the global business unit teams managing the dental product portfolio, serve as a member of the Executive Management Team and report directly to Chief Executive Officer, Simon Campion. David Ferguson joins Dentsply Sirona with 25 years of experience in MedTech and healthcare with a proven track record of delivering results, competing in a global marketplace and leading global product strategy. Mr. Ferguson has se

      3/17/25 8:45:57 AM ET
      $XRAY
      Medical/Dental Instruments
      Health Care
    • Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

      CHARLOTTE, N.C., Feb. 06, 2025 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ:XRAY) today announced that Michael J. Barber and Daniel T. Scavilla have been appointed to its Board of Directors (the "Board"), effective February 5, 2025. Mr. Barber brings over 40 years of experience in product management and innovation, including executive leadership roles at GE, where he was responsible for the transformation of the company's digital X-Ray program. Mr. Scavilla, currently CEO of Globus Medical, is a seasoned executive with a deep skillset in commercial deployment and business integration, having successfully led the merger of Globus and NuVasive. Mr. B

      2/6/25 8:30:00 AM ET
      $EXAS
      $GE
      $GMED
      $XRAY
      Medical Specialities
      Health Care
      Consumer Electronics/Appliances
      Technology